Japanese approval strategically important for ALK

Last week, Danish allergy group ALK obtained Japanese authorities’ approval for using a tablet vaccine, too. It fuels the company’s hope that the same approval can be achieved in other markets. However, the rival Stallergenes made the same move so the competition continues to be fierce.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles